Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2002
|
| gptkbp:ATCCode |
J05AF08
|
| gptkbp:CASNumber |
142340-99-6
|
| gptkbp:chemicalFormula |
C20H32N5O8P
|
| gptkbp:contraindication |
severe renal impairment
|
| gptkbp:drugClass |
antiviral
|
| gptkbp:eliminationHalfLife |
5-7 hours
|
| gptkbp:genericName |
gptkb:adefovir_dipivoxil
|
| https://www.w3.org/2000/01/rdf-schema#label |
Hepsera
|
| gptkbp:indication |
hepatitis B virus infection
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Gilead_Sciences
|
| gptkbp:marketedIn |
gptkb:European_Union
gptkb:United_States |
| gptkbp:mechanismOfAction |
nucleotide analogue reverse transcriptase inhibitor
|
| gptkbp:pregnancyCategory |
C
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nephrotoxicity
lactic acidosis asthenia |
| gptkbp:usedFor |
chronic hepatitis B
|
| gptkbp:bfsParent |
gptkb:adefovir
|
| gptkbp:bfsLayer |
6
|